Resource Logo

CMV, RS-79070: community concern as major drug's development suspended.


AIDS Treat News. 1997 May 1;(No 270):1-2. Unique Identifier : AIDSLINE

Due to the declining numbers of cytomegalovirus retinitis cases, Hoffmann-La Roche has suspended plans for future Phase III trials of RS-79070, a prodrug of ganciclovir. RS-79070 provides a higher level of ganciclovir in the blood once it is absorbed. Even though this drug may replace ocular implants or intravenous treatments, it cannot be marketed without conducting expensive Phase III clinical trials. It is hoped that results from continuing Phase II trials will revive the possibility of performing Phase III studies.

*Antiviral Agents/THERAPEUTIC USE *Cytomegalovirus Retinitis/DRUG THERAPY *Ganciclovir/THERAPEUTIC USE *Prodrugs/THERAPEUTIC USE


Information in this article was accurate in September 30, 1997. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.